Difference between revisions of "Low-grade oncocytic renal tumour"

Jump to navigation Jump to search
no edit summary
(4 intermediate revisions by the same user not shown)
Line 10: Line 10:
| IHC        = CK7 +ve, CD117 -ve, GATA3 +ve, [[PAX8]] +ve
| IHC        = CK7 +ve, CD117 -ve, GATA3 +ve, [[PAX8]] +ve
| EM        =  
| EM        =  
| Molecular  =
| Molecular  = TSC/mTOR pathway mutation
| IF        =
| IF        =
| Gross      =  
| Gross      =  
Line 19: Line 19:
| Clinicalhx = often incidentally discovered mass
| Clinicalhx = often incidentally discovered mass
| Signs      =
| Signs      =
| Symptoms  =
| Symptoms  =  
| Prevalence =
| Prevalence =
| Bloodwork  =
| Bloodwork  =
Line 29: Line 29:
}}
}}
'''Low-grade oncocytic renal tumour''', abbreviated '''LOT''', is an unusual [[renal tumour]] that does not neatly fit into any WHO renal neoplasia category.  It is also known as '''renal oncocytic tumour that is CD117 negative and CK7 positive'''.  
'''Low-grade oncocytic renal tumour''', abbreviated '''LOT''', is an unusual [[renal tumour]] that does not neatly fit into any WHO renal neoplasia category.  It is also known as '''renal oncocytic tumour that is CD117 negative and CK7 positive'''.  
''Low-grade oncocytic tumour'' directs to here.


Whether it is a distinct entity is not clear as of 2019.<ref name=pmid30895640/>  It can be considered an emerging entity that may be in the WHO classification of renal neoplasia in the future.<ref name=pmid31936678>{{cite journal |authors=Siadat F, Trpkov K |title=ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification |journal=Cancers (Basel) |volume=12 |issue=1 |pages= |date=January 2020 |pmid=31936678 |pmc=7017067 |doi=10.3390/cancers12010168 |url=}}</ref>
Whether it is a distinct entity is not clear as of 2019.<ref name=pmid30895640/>  It can be considered an emerging entity that may be in the WHO classification of renal neoplasia in the future.<ref name=pmid31936678>{{cite journal |authors=Siadat F, Trpkov K |title=ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification |journal=Cancers (Basel) |volume=12 |issue=1 |pages= |date=January 2020 |pmid=31936678 |pmc=7017067 |doi=10.3390/cancers12010168 |url=}}</ref>
Line 76: Line 78:
*CK20 -ve.
*CK20 -ve.
*CD10 -ve.
*CD10 -ve.
==Molecular==
*[[Renal neoplasms with TSC/mTOR pathway mutations|TSC/mTOR pathway mutation]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref>


==Sign out==
==Sign out==
<pre>
<pre>
Right Kidney Mass, Biopsy:
Right Kidney Mass, Biopsy:
Line 98: Line 102:


==References==
==References==
{{Reflist|1}}
{{Reflist|2}}


[[Category:Diagnosis]]
[[Category:Diagnosis]]
[[Category:Genitourinary pathology]]
[[Category:Genitourinary pathology]]
48,460

edits

Navigation menu